While the downgrade from Buy to Outperform might initially seem negative, it's important to note that Outperform still indicates that the analyst expects the stock to do better than the market average. Furthermore, the increase in price target from $42 to $51 suggests that the analyst sees significant upside potential for the stock. Therefore, the impact on the stock is likely to be neutral in the short term.